Concert Pharmaceuticals, Inc. (CNCE): Product News News

CNCE – Announces FDA has granted Fast Track designation for CTP-543.

Key Facts Surrounding This News Item

  • CNCE had a POWR Rating of B (Buy) coming into today.
  • CNCE was 1.62% above its 10-Day Moving Average coming into today.
  • CNCE was 2.84% above its 20-Day Moving Average coming into today.
  • CNCE was 19.06% above its 50-Day Moving Average coming into today.
  • CNCE was 44.40% above its 100-Day Moving Average coming into today.
  • CNCE was 63.65% above its 200-Day Moving Average coming into today.
  • CNCE had returned +7.00% year-to-date leading up to today’s news, versus a +3.47% return from the benchmark S&P 500 during the same period.

More Info About Concert Pharmaceuticals, Inc. (CNCE)

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts. View our full CNCE ticker page with ratings, news, and more.

CNCE at a Glance

CNCE Current POWR Rating™
Overall POWR Rating™
CNCE Current Price $13.96 0.85%
More CNCE Ratings, Data, and News

CNCE Price Reaction

The day of this event (Jan. 12, 2018)
CNCE Closing Price$20.15 27.20%
CNCE Volume3,408,700
1,170.31% from avg
Leading up to this event
CNCE 1-mo return6.46%
After this event
CNCE 1-day return43.87%
CNCE 3-day return40.44%
CNCE 5-day return40.44%

CNCE Price Chart

The Top Stocks For 2019

More Concert Pharmaceuticals, Inc. (CNCE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CNCE News
Page generated in 0.9547 seconds.